• Chimie et Matériaux
  • Santé et Nutrition

Agents infectieux, Résistance et Chimiothérapie (AGIR)

Unité de recherche - UR 4294

Description

Le laboratoire AGIR s’intéresse au développement de nouvelles molécules anti-infectieuses, possédant des propriétés antimicrobiennes propres et/ou capables de contrer les phénomènes de résistance liés à un défaut de concentration des antibiotiques au sein des micro-organismes (analogues de sidérophores, inhibiteurs de pompes à efflux…).

Les thématiques de recherche de l'équipe s'articulent plus particulièrement autour de 4 groupes d'agents infectieux, retrouvés en clinique :
- Bactéries ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Actinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., Escherichia coli) (exemple: infections nosocomiales)
- Mycobactéries (typiques et atypiques) (exemple: tuberculose)
- Plasmodium falciparum (exemple: paludisme)
- Virus BK

Contacts

  • Laurence Marquis
    Secrétariat
  • Pascal Sonnet
    Direction
  • Etienne BROCHOT

Informations

Batiment H, Chemin du Thil et Centre Universitaire de Recherche en Santé - CURS, Avenue Laennec
Pôle K - CHU Sud D408 (René Laennec)
80054 AMIENS Cedex 1

https://agir.u-picardie.fr/

Agents infectieux, Résistance et Chimiothérapie

Effectif

Effectif total : 46

Personnel de recherche : 28

Personnel d'appui à la recherche : 8

Expertises

Compétences

- Epidemiological studies and clinical research (characterization of biomolecular targets in epidemic strains)
- Design and synthesis of novel anti-infective heterocyclic compounds (siderophore analogues, quorum sensing inhibitors with anti-virulence potential, arylamino alcohols, etc.)
- Peptide synthesis (antimicrobial peptides, AMPs)
- Physicochemical evaluation and in silico structure–activity relationship (SAR) studies
- In vitro biological evaluation (efficacy, cytotoxicity, membrane permeability) through the development of cellular models, and investigation of mechanisms of action using biomolecular approaches (commercial or clinical strains)
- Ex vivo and in vivo biological evaluation using animal models (efficacy, toxicity, pharmacokinetics, pharmacodynamics)

Exemple(s) de projets

1. SEAPAL Project – “Synthesis and Study of New Enantiomerically Pure Antimalarial Compounds”
Synthesis and evaluation of novel amino alcohol derivatives with a quinoline scaffold, designed to overcome resistance mechanisms in Plasmodium falciparum.

2. SYNETUBER Project – “Synthesis and Study of New Antitubercular Agents”
Synthesis and biological evaluation of novel antitubercular compounds (heterocyclic derivatives and/or antimicrobial peptides, AMPs).

3. SASAB Project – “Synthesis and Study of Broad-Spectrum Antibacterial Siderophore Analogues”
Synthesis and investigation of new siderophore analogues (iron transporters) used as antibiotic delivery vectors (“Trojan horse” strategy).

4. BKSTRIP Project – “Development of a Rapid Urinary Screening Test for BK Virus”
Development of a urine dipstick test enabling early detection of BK virus reactivation to improve patient monitoring in post-transplant settings.

5. SALICOV Project – “Evaluation of Saliva Sampling Versus Nasopharyngeal Sampling for SARS-CoV-2 Diagnosis by RT-PCR”
Assessment of the diagnostic performance of saliva-based sampling compared to nasopharyngeal swabs for SARS-CoV-2 detection

Exemple(s) de publications

'1- Froment, A.; Delomez, J.; Da Nascimento, S.; Dassonville-Klimpt, A.; Andréjak, C.; Peltier, F.; Joseph, C.; Sonnet, P.; Lanoix, J.-P. Efficacy of Mefloquine and Its Enantiomers in a Murine Model of Mycobacterium Avium Infection. PLoS One 2024, 19, e0311167, doi:10.1371/journal.pone.0311167.
2- Brochot, E.; Fourdinier, O.; Demey, B.; Aubry, A.; Collet, L.; Descamps, V.; Morel, V.; Gaboriaud, P.; Castelain, S.; Helle, F.; et al. Development of a Urinary Antigen Test for BK Polyomavirus to Help Clinicians in Patients’ Follow-Up. J Virol Methods 2025, 333, 115113, doi:10.1016/j.jviromet.2025.115113.
3- Ramos-Martín, F.; Peltier, F.; Oueslati, S.; Cousin, L.; Rima, M.; Perret, M.; Bibens, L.; Sevin, E.; Antonietti, V.; Da Nascimento, S.; Sarazin, C.; Gosselet, F.; Naas, T.; Sonnet, P.; D’Amelio, N. Harnessing the Power of Anti-Amyloidogenic Polyglutamine Binding Peptide 1: A Computational and Biophysical Approach to Antimicrobial Prediction. Int J Biol Macromol 2025, 318, 144938, doi:10.1016/j.ijbiomac.2025.144938.
4- Demey, B.; Aubry, A.; Morel, V.; Collet, L.; Francois, C.; Castelain, S.; Helle, F.; Brochot, E. JC Polyomavirus-Encoded miRNA Jcv-miR-J1-5p Downregulates BK Polyomavirus Infection. Antiviral Res 2026, 245, 106313, doi:10.1016/j.antiviral.2025.106313.
5- Tisnerat, C.; Schneider, J.; Mustière, R.; Herrero, A.; Momha, R.; Damiani, C.; Agnamey, P.; Totet, A.; Marchivie, M.; Guillon, J.; Dassonville-Klimpt, A.; P. Sonnet, P. Synthesis of New Enantiopure Aminoalchohol Fluorenes as Promising Antimalarial Compounds. ChemMedChem 2025, 20, e202400790, doi:10.1002/cmdc.202400790.

Découvrez la liste complète des publications : https://agir.u-picardie.fr/production-scientifique/publications/

Collaborations/Partenaires/Clients scientifiques

National Collaborations:
University of Rouen; Institut Pasteur de Lille; CIIL (Center for Infection and Immunity of Lille); University of Technology of Compiègne; Molecular Chemistry Institute of Reims; University of Strasbourg; SATT Nord; MAVIVH (University of Tours); French Armed Forces Biomedical Research Institute; LBHE (University of Artois).

The research unit is strongly involved in the FHU “Respire” (2021–2026), led by Prof. C. Andrejak. This University Hospital Federation brings together 4 university hospitals (CHUs), 6 universities (Amiens, Rouen, Caen, Lille, Artois, and the University of Technology of Compiègne), and the Institut Pasteur de Lille. Its main objective is to improve respiratory health through an integrated approach that considers host characteristics, environmental factors, pathogens, and their interactions at the pulmonary level.

Collaborations/Partenaires/Clients privés

MAST diagnostic, Sanofi, Pharm'aging, Theranexus, Servier

Offres de services

Prestations de service

Services covering our expertises

AGIR is equipped with Biosafety Level 2 (BSL-2) microbiology laboratories and a wide range of instruments, including a fluorescence microscope for medium-throughput screening, biological safety cabinets (BSCs), CO₂ incubators, real-time thermocyclers, and a high-throughput sequencing platform (NGS). The unit also has centrifuges and ultracentrifuges, an electroporator, and an automated fraction collector coupled with a qNano system (for measuring size, charge, and concentration of extracellular vesicles).

The unit is also equipped for chemical synthesis and physicochemical characterization of compounds, including: two peptide synthesizers; a quadrupole mass spectrometer coupled to a high-performance liquid chromatography system (HPLC); a quadrupole mass spectrometer coupled to a gas chromatography system (GC); instruments for physicochemical property measurements; three HPLC systems (analytical and preparative, Shimadzu); a circular dichroism spectrometer; an FTIR infrared spectrometer; cryostats; a microwave reactor; two flash purification systems; a solvent purification system; a polarimeter; and a 60 MHz NMR spectrometer.

Prestations de conseil

Services covering our expertises

Equipements

Detailed list : 🡭

Matériel biologique

Bactéries ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acitenobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., Escherichia coli), MYCOBACTÉRIES (M. bovis DSM 43990, M. smegmatis DSM 43465Mycobacterium tuberculosis, M. bohemicum DSM 44277, MAC 101 et M. xenopi ATCC 19971), PLASMODIUM FALCIPARUM, VIRUS BK. Modèles murins (souris) utilisées pour évaluation ex vivo et in vivo.

Écosystème

Établissements / Organismes de rattachement

Établissement(s) partenaires

Domaines d'activités stratégiques régionales

  • Chimie et Matériaux
    • Chimie organique
  • Santé et Nutrition
    • Génétique, bio-marqueurs et biomolécules